lunes, 5 de octubre de 2009

Drug Information Update- Cardiovascular and Renal Drugs Advisory Committee on 12/7/09



Drug Information Update- Cardiovascular and Renal Drugs Advisory Committee on 12/7/09

The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
On December 7, 2009, the Cardiovascular and Renal Drugs Advisory Committee will discuss new drug application (NDA) 21560, for everolimus oral tablets, by Novartis Pharmaceuticals Corporation, to be used in patients with kidney transplants to prevent rejection of the transplanted kidney.
For more information, please visit: Everolimus

abrir aquí:
http://www.federalregister.gov/OFRUpload/OFRData/2009-24015_PI.pdf

No hay comentarios:

Publicar un comentario